X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB LUPIN LTD UNICHEM LAB/
LUPIN LTD
 
P/E (TTM) x -64.1 28.3 - View Chart
P/BV x 0.7 3.0 24.3% View Chart
Dividend Yield % 2.4 0.6 419.6%  

Financials

 UNICHEM LAB   LUPIN LTD
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
LUPIN LTD
Mar-18
UNICHEM LAB/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3821,465 26.1%   
Low Rs234727 32.2%   
Sales per share (Unadj.) Rs116.3349.6 33.3%  
Earnings per share (Unadj.) Rs-18.95.6 -340.4%  
Cash flow per share (Unadj.) Rs-11.729.6 -39.7%  
Dividends per share (Unadj.) Rs5.005.00 100.0%  
Dividend yield (eoy) %1.60.5 355.8%  
Book value per share (Unadj.) Rs381.0300.3 126.9%  
Shares outstanding (eoy) m70.34452.08 15.6%   
Bonus/Rights/Conversions BBESOPS-  
Price / Sales ratio x2.63.1 84.5%   
Avg P/E ratio x-16.3197.2 -8.3%  
P/CF ratio (eoy) x-26.237.1 -70.8%  
Price / Book Value ratio x0.83.6 22.2%  
Dividend payout %-26.490.0 -29.4%   
Avg Mkt Cap Rs m21,668495,502 4.4%   
No. of employees `0002.317.0 13.4%   
Total wages/salary Rs m2,00628,647 7.0%   
Avg. sales/employee Rs Th3,587.89,273.6 38.7%   
Avg. wages/employee Rs Th880.01,681.0 52.4%   
Avg. net profit/employee Rs Th-583.7147.4 -395.9%   
INCOME DATA
Net Sales Rs m8,180158,042 5.2%  
Other income Rs m6101,504 40.6%   
Total revenues Rs m8,790159,545 5.5%   
Gross profit Rs m-1,32031,475 -4.2%  
Depreciation Rs m50510,859 4.7%   
Interest Rs m802,044 3.9%   
Profit before tax Rs m-1,29520,076 -6.5%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m-235 -6.3%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m332,885 1.2%   
Profit after tax Rs m-1,3312,513 -53.0%  
Gross profit margin %-16.119.9 -81.0%  
Effective tax rate %-2.614.4 -18.0%   
Net profit margin %-16.31.6 -1,023.4%  
BALANCE SHEET DATA
Current assets Rs m23,318122,095 19.1%   
Current liabilities Rs m4,63550,956 9.1%   
Net working cap to sales %228.445.0 507.4%  
Current ratio x5.02.4 209.9%  
Inventory Days Days12285 143.9%  
Debtors Days Days121120 101.3%  
Net fixed assets Rs m8,163129,876 6.3%   
Share capital Rs m141904 15.6%   
"Free" reserves Rs m26,660134,866 19.8%   
Net worth Rs m26,801135,771 19.7%   
Long term debt Rs m364,245 0.0%   
Total assets Rs m31,890263,054 12.1%  
Interest coverage x-15.210.8 -140.2%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.30.6 42.7%   
Return on assets %-3.91.7 -226.5%  
Return on equity %-5.01.9 -268.3%  
Return on capital %-4.53.7 -122.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,35653,141 8.2%   
Fx outflow Rs m019,335 0.0%   
Net fx Rs m4,35633,807 12.9%   
CASH FLOW
From Operations Rs m-1,12317,512 -6.4%  
From Investments Rs m16,487-14,073 -117.2%  
From Financial Activity Rs m-8,811-14,921 59.1%  
Net Cashflow Rs m6,552-11,482 -57.1%  

Share Holding

Indian Promoters % 50.1 46.6 107.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 15.1 11.3 133.6%  
FIIs % 3.0 31.9 9.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 10.1 313.9%  
Shareholders   20,176 98,259 20.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   SANOFI INDIA  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare UNICHEM LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 21, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - ASTRAZENECA PHARMA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS